Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Dec 2018 04:35 PM
RNS
Price Monitoring Extension
17 Dec 2018 07:00 AM
RNS
Appointment of Nominated Adviser
07 Dec 2018 07:00 AM
RNS
Update on Corporate Activities
29 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
29 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
28 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
28 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
23 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
23 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
21 Nov 2018 04:40 PM
RNS
Second Price Monitoring Extn
21 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
07 Nov 2018 04:35 PM
RNS
Price Monitoring Extension
01 Nov 2018 01:38 PM
RNS
Nominated Adviser Status
26 Sep 2018 07:00 AM
RNS
Interim Results
19 Sep 2018 07:00 AM
RNS
Appointment of Joint Brokers
07 Sep 2018 07:00 AM
RNS
Corporate Update
10 Jul 2018 04:40 PM
RNS
Second Price Monitoring Extn
10 Jul 2018 04:35 PM
RNS
Price Monitoring Extension
28 Jun 2018 12:16 PM
RNS
Result of AGM
14 Jun 2018 07:00 AM
RNS
Results of CIDP Pre-Clinical Data
06 Jun 2018 07:00 AM
RNS
Notice of AGM & Posting of Annual Report
29 May 2018 07:00 AM
RNS
Update on Pivotal Phase III Trial of Lupuzor
29 May 2018 07:00 AM
RNS
Final Results
24 Apr 2018 11:59 AM
RNS
Holding(s) in Company
20 Apr 2018 08:24 AM
RNS
Holding(s) in Company
19 Apr 2018 08:05 AM
RNS
Holding(s) in Company
17 Apr 2018 07:00 AM
RNS
Topline results of Lupuzor Pivotal Phase III Trial
28 Mar 2018 07:00 AM
RNS
Appointment of Joint Broker
23 Mar 2018 07:00 AM
RNS
Lupuzor Pivotal Phase III Study Update
05 Mar 2018 04:13 PM
RNS
AIM Notice (17)
15 Feb 2018 07:00 AM
RNS
London Investor Evening
09 Feb 2018 02:00 PM
RNS
Holding(s) in Company
07 Feb 2018 09:35 AM
RNS
Holding(s) in Company
05 Feb 2018 07:00 AM
RNS
Holding(s) in Company
31 Jan 2018 10:23 AM
RNS
Holding(s) in Company
24 Jan 2018 07:00 AM
RNS
Successful Placing to Raise £10 Million
18 Jan 2018 07:00 AM
RNS
Completion of LupuzorT Pivotal Phase III Study
21 Dec 2017 07:05 AM
RNS
Grant of Options
21 Dec 2017 07:00 AM
RNS
Last patient completes dosing in LupuzorT Trial
28 Nov 2017 12:00 PM
RNS
Holding(s) in Company
24 Nov 2017 01:32 PM
RNS
Grant of Options
02 Nov 2017 07:00 AM
RNS
Update on LupuzorT Pivotal Phase III Study
16 Oct 2017 03:29 PM
RNS
Holding(s) in Company
04 Oct 2017 07:00 AM
RNS
Completion of Lanstead Sharing Agreement
27 Sep 2017 07:00 AM
RNS
Interim Results
26 Sep 2017 07:00 AM
RNS
Preparation of Lupuzor'sT Regulatory Submissions
21 Sep 2017 07:00 AM
RNS
Update on LupuzorT Pivotal Phase III Study
19 Sep 2017 07:00 AM
RNS
Notification of Interim Results
18 Aug 2017 05:09 PM
RNS
AIM Rule 17 Notice
12 Jul 2017 11:00 AM
RNS
Grant of Options

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100

Latest directors dealings